07:37 AM EDT, 10/27/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Monday that Omvoh-treated patients with moderately to severely active ulcerative colitis saw early improvements in bowel urgency severity, frequency and stool deferral time by week 12, with the results continuing to improve through 28 weeks.

Results from a Phase 3b trial showed that bowel urgency severity was lowered by 52% at week 28, while patients reported a 55% reduction in urgency frequency from baseline in the number of times they experienced bowel urgency per day.

The proportion of patients who were able to delay a bowel movement for at least 15 minutes or experienced no urgency in the past 24 hours increased to 15.7% at week 12 and 29.7% at week 28 from 4.1% at baseline, the company said.

The safety profile was consistent with the known safety profile of Omvoh, with no new safety signals observed, Lilly said.